Vancomycin-Resistant Staphylococcus Aureus Infections Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Injection
1.2.3 Pills
1.3 Market by Application
1.3.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Perspective (2017-2028)
2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Growth Trends by Region
2.2.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size by Region (2017-2022)
2.2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Region (2023-2028)
2.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Dynamics
2.3.1 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Industry Trends
2.3.2 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Drivers
2.3.3 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Challenges
2.3.4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players by Revenue
3.1.1 Global Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players by Revenue (2017-2022)
3.1.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Players (2017-2022)
3.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue
3.4 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Concentration Ratio
3.4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in 2021
3.5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Key Players Head office and Area Served
3.6 Key Players Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Solution and Service
3.7 Date of Enter into Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Breakdown Data by Type
4.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size by Type (2017-2022)
4.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Type (2023-2028)
5 Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Breakdown Data by Application
5.1 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Historic Market Size by Application (2017-2022)
5.2 Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2017-2028)
6.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
6.2.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022)
6.2.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028)
6.2.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type (2017-2028)
6.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
6.3.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022)
6.3.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028)
6.3.3 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application (2017-2028)
6.4 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
6.4.1 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022)
6.4.2 North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2017-2028)
7.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
7.2.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022)
7.2.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028)
7.2.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type (2017-2028)
7.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
7.3.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022)
7.3.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028)
7.3.3 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application (2017-2028)
7.4 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
7.4.1 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022)
7.4.2 Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2017-2028)
8.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
8.2.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type (2017-2028)
8.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
8.3.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application (2017-2028)
8.4 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region
8.4.1 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2017-2028)
9.2 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
9.2.1 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022)
9.2.2 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028)
9.2.3 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type (2017-2028)
9.3 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
9.3.1 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022)
9.3.2 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028)
9.3.3 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application (2017-2028)
9.4 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
9.4.1 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022)
9.4.2 Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (2017-2028)
10.2 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type
10.2.1 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type (2017-2028)
10.3 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application
10.3.1 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application (2017-2028)
10.4 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country
10.4.1 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Eli Lily
11.1.1 Eli Lily Company Details
11.1.2 Eli Lily Business Overview
11.1.3 Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.1.4 Eli Lily Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.1.5 Eli Lily Recent Developments
11.2 Wockhardt Ltd
11.2.1 Wockhardt Ltd Company Details
11.2.2 Wockhardt Ltd Business Overview
11.2.3 Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.2.4 Wockhardt Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.2.5 Wockhardt Ltd Recent Developments
11.3 Amprologix Ltd
11.3.1 Amprologix Ltd Company Details
11.3.2 Amprologix Ltd Business Overview
11.3.3 Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.3.4 Amprologix Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.3.5 Amprologix Ltd Recent Developments
11.4 CrystalGenomics Inc
11.4.1 CrystalGenomics Inc Company Details
11.4.2 CrystalGenomics Inc Business Overview
11.4.3 CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.4.4 CrystalGenomics Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.4.5 CrystalGenomics Inc Recent Developments
11.5 Debiopharm International SA
11.5.1 Debiopharm International SA Company Details
11.5.2 Debiopharm International SA Business Overview
11.5.3 Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.5.4 Debiopharm International SA Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.5.5 Debiopharm International SA Recent Developments
11.6 Destiny Pharma Plc
11.6.1 Destiny Pharma Plc Company Details
11.6.2 Destiny Pharma Plc Business Overview
11.6.3 Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.6.4 Destiny Pharma Plc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.6.5 Destiny Pharma Plc Recent Developments
11.7 Lysimmune BioScience
11.7.1 Lysimmune BioScience Company Details
11.7.2 Lysimmune BioScience Business Overview
11.7.3 Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.7.4 Lysimmune BioScience Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.7.5 Lysimmune BioScience Recent Developments
11.8 Roivant Sciences Ltd
11.8.1 Roivant Sciences Ltd Company Details
11.8.2 Roivant Sciences Ltd Business Overview
11.8.3 Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.8.4 Roivant Sciences Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.8.5 Roivant Sciences Ltd Recent Developments
11.9 TGV-Inhalonix Inc
11.9.1 TGV-Inhalonix Inc Company Details
11.9.2 TGV-Inhalonix Inc Business Overview
11.9.3 TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.9.4 TGV-Inhalonix Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.9.5 TGV-Inhalonix Inc Recent Developments
11.10 Therapeutic Systems Research Laboratories Inc
11.10.1 Therapeutic Systems Research Laboratories Inc Company Details
11.10.2 Therapeutic Systems Research Laboratories Inc Business Overview
11.10.3 Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Introduction
11.10.4 Therapeutic Systems Research Laboratories Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
11.10.5 Therapeutic Systems Research Laboratories Inc Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Injection
Table 3. Key Players of Pills
Table 4. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 5. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 6. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2017-2022) & (US$ Million)
Table 7. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Region (2017-2022)
Table 8. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 9. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Region (2023-2028)
Table 10. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Trends
Table 11. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Drivers
Table 12. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Challenges
Table 13. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Restraints
Table 14. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue by Players (2017-2022) & (US$ Million)
Table 15. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Players (2017-2022)
Table 16. Global Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections as of 2021)
Table 17. Ranking of Global Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Companies by Revenue (US$ Million) in 2021
Table 18. Global 5 Largest Players Market Share by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue (CR5 and HHI) & (2017-2022)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product Solution and Service
Table 21. Date of Enter into Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022) & (US$ Million)
Table 24. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2017-2022)
Table 25. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 26. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Market Share by Type (2023-2028)
Table 27. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022) & (US$ Million)
Table 28. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Application (2017-2022)
Table 29. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 30. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue Share by Application (2023-2028)
Table 31. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022) & (US$ Million)
Table 32. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028) & (US$ Million)
Table 33. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022) & (US$ Million)
Table 34. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028) & (US$ Million)
Table 35. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022) & (US$ Million)
Table 38. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028) & (US$ Million)
Table 39. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022) & (US$ Million)
Table 40. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028) & (US$ Million)
Table 41. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022) & (US$ Million)
Table 42. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028) & (US$ Million)
Table 43. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022) & (US$ Million)
Table 44. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028) & (US$ Million)
Table 45. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022) & (US$ Million)
Table 46. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028) & (US$ Million)
Table 47. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2017-2022) & (US$ Million)
Table 48. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Region (2023-2028) & (US$ Million)
Table 49. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022) & (US$ Million)
Table 50. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028) & (US$ Million)
Table 51. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022) & (US$ Million)
Table 52. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028) & (US$ Million)
Table 53. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022) & (US$ Million)
Table 54. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028) & (US$ Million)
Table 55. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2017-2022) & (US$ Million)
Table 56. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Type (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Application (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size by Country (2023-2028) & (US$ Million)
Table 61. Eli Lily Company Details
Table 62. Eli Lily Business Overview
Table 63. Eli Lily Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 64. Eli Lily Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 65. Eli Lily Recent Developments
Table 66. Wockhardt Ltd Company Details
Table 67. Wockhardt Ltd Business Overview
Table 68. Wockhardt Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 69. Wockhardt Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 70. Wockhardt Ltd Recent Developments
Table 71. Amprologix Ltd Company Details
Table 72. Amprologix Ltd Business Overview
Table 73. Amprologix Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 74. Amprologix Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 75. Amprologix Ltd Recent Developments
Table 76. CrystalGenomics Inc Company Details
Table 77. CrystalGenomics Inc Business Overview
Table 78. CrystalGenomics Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 79. CrystalGenomics Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 80. CrystalGenomics Inc Recent Developments
Table 81. Debiopharm International SA Company Details
Table 82. Debiopharm International SA Business Overview
Table 83. Debiopharm International SA Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 84. Debiopharm International SA Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 85. Debiopharm International SA Recent Developments
Table 86. Destiny Pharma Plc Company Details
Table 87. Destiny Pharma Plc Business Overview
Table 88. Destiny Pharma Plc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 89. Destiny Pharma Plc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 90. Destiny Pharma Plc Recent Developments
Table 91. Lysimmune BioScience Company Details
Table 92. Lysimmune BioScience Business Overview
Table 93. Lysimmune BioScience Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 94. Lysimmune BioScience Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 95. Lysimmune BioScience Recent Developments
Table 96. Roivant Sciences Ltd Company Details
Table 97. Roivant Sciences Ltd Business Overview
Table 98. Roivant Sciences Ltd Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 99. Roivant Sciences Ltd Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 100. Roivant Sciences Ltd Recent Developments
Table 101. TGV-Inhalonix Inc Company Details
Table 102. TGV-Inhalonix Inc Business Overview
Table 103. TGV-Inhalonix Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 104. TGV-Inhalonix Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 105. TGV-Inhalonix Inc Recent Developments
Table 106. Therapeutic Systems Research Laboratories Inc Company Details
Table 107. Therapeutic Systems Research Laboratories Inc Business Overview
Table 108. Therapeutic Systems Research Laboratories Inc Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Product
Table 109. Therapeutic Systems Research Laboratories Inc Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022) & (US$ Million)
Table 110. Therapeutic Systems Research Laboratories Inc Recent Developments
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Type: 2021 VS 2028
Figure 2. Injection Features
Figure 3. Pills Features
Figure 4. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Application: 2021 VS 2028
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Other Case Studies
Figure 8. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Report Years Considered
Figure 9. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 10. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 11. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Region: 2021 VS 2028
Figure 12. Global Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Share by Players in 2021
Figure 13. Global Top Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections as of 2021)
Figure 14. The Top 10 and 5 Players Market Share by Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Revenue in 2021
Figure 15. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY (2017-2028) & (US$ Million)
Figure 16. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2017-2028)
Figure 17. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2017-2028)
Figure 18. North America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share by Country (2017-2028)
Figure 19. United States Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 20. Canada Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 21. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY (2017-2028) & (US$ Million)
Figure 22. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2017-2028)
Figure 23. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2017-2028)
Figure 24. Europe Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share by Country (2017-2028)
Figure 25. Germany Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. France Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. U.K. Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 28. Italy Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. Russia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. Nordic Countries Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Asia-Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY (2017-2028) & (US$ Million)
Figure 32. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2017-2028)
Figure 33. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2017-2028)
Figure 34. Asia Pacific Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share by Region (2017-2028)
Figure 35. China Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 36. Japan Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. South Korea Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. Southeast Asia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. India Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. Australia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 41. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY (2017-2028) & (US$ Million)
Figure 42. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2017-2028)
Figure 43. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2017-2028)
Figure 44. Latin America Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share by Country (2017-2028)
Figure 45. Mexico Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Brazil Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY (2017-2028) & (US$ Million)
Figure 48. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Type (2017-2028)
Figure 49. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Market Share by Application (2017-2028)
Figure 50. Middle East and Africa Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size Share by Country (2017-2028)
Figure 51. Turkey Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 52. Saudi Arabia Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 53. UAE Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 54. Eli Lily Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 55. Wockhardt Ltd Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 56. Amprologix Ltd Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 57. CrystalGenomics Inc Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 58. Debiopharm International SA Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 59. Destiny Pharma Plc Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 60. Lysimmune BioScience Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 61. Roivant Sciences Ltd Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 62. TGV-Inhalonix Inc Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 63. Therapeutic Systems Research Laboratories Inc Revenue Growth Rate in Vancomycin-Resistant Staphylococcus Aureus (VRSA) Infections Business (2017-2022)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Industry Market Size
